Overview

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Status:
Completed
Trial end date:
2016-10-17
Target enrollment:
Participant gender:
Summary
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
Phase:
Phase 2
Details
Lead Sponsor:
Novan, Inc.
Collaborator:
PPD